Pamela Esposito, Director at Kymera Therapeutics, Inc. (KYMR), sold 2,500 shares at $49.00 ($123K) on 2024-12-02, disclosed to the SEC on 2024-12-02.
Scheduled sale ($122k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KYMR | SELL | 2026-01-20 | $707K | — | Filing → |
| KYMR | SELL | 2025-12-17 | $4.4M | — | Filing → |
| KYMR | SELL | 2025-06-03 | $245K | — | Filing → |